Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|A071702||Alliance||A Phase II Study of Checkpoint Blockade Immunotherapy in Patients with Somatically Hypermutated Recurrent Glioblastoma||Adult CIRB - Late Phase Emphasis||Available to Open|
|A171601||Alliance||A phase II trial assessing the tolerability of palbociclib in combination with letrozole or fulvestrant in patients aged 70 and older with estrogen receptor-positive, HER2-negative metastatic breast cancer||Cancer Prevention and Control CIRB||Available to Open|
|A091202||Alliance||A Phase II Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist; Efatutazone in Patients with Previously Treated; Unresectable Myxoid Liposarcoma||Adult CIRB - Early Phase Emphasis||Available to Open|
|A231602CD||Alliance||Assessing Financial Difficulty in Patients with Blood Cancers||Cancer Prevention and Control CIRB||Available to Open|
|A191402CD||Alliance||Testing Decision Aids to Improve Prostate Cancer Decisions for Minority Men||Cancer Prevention and Control CIRB||Available to Open|
|A222001||Alliance||A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Oxybutynin Versus Placebo for the Treatment of Hot Flashes in Men Receiving Androgen Deprivation Therapy||Cancer Prevention and Control CIRB||Available to Open|
|A221602||Alliance||Olanzapine with or without fosaprepitant for the prevention of chemotherapy induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC): A Phase III Randomized, Double Blind, Placebo-Controlled Trial||Cancer Prevention and Control CIRB||Available to Open|
|A051301||Alliance||A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation versus Placebo in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype||Adult CIRB - Late Phase Emphasis||Available to Open|
|A031704||Alliance||PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer [PDIGREE]||Adult CIRB - Late Phase Emphasis||Available to Open|
|A011801||Alliance||The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): CompassHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinb||Adult CIRB - Late Phase Emphasis||Available to Open|